<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>328</serviceExecutionTime><Drug id="84233"><DrugName>etanercept biosimilar, Zhejiang Hisun Pharmaceutical</DrugName><DrugNamesKey><Name id="42756822">etanercept</Name></DrugNamesKey><DrugSynonyms><Name><Value>etanercept</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>etanercept biosimilar, Zhejiang Hisun Pharmaceutical</Value></Name><Name><Value>Anbainuo</Value></Name></DrugSynonyms><CompanyOriginator id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1019688" type="Company"><TargetEntity id="4295865361" type="organizationId">Zhejiang Hisun Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="398" type="ciIndication"><TargetEntity id="M45" type="ICD10"></TargetEntity><TargetEntity id="720.0" type="ICD9"></TargetEntity><TargetEntity id="10002556" type="MEDDRA"></TargetEntity><TargetEntity id="D013167" type="MeSH"></TargetEntity><TargetEntity id="-605402220" type="omicsDisease"></TargetEntity><TargetEntity id="752" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="PTGT-02033" type="ciTarget"><TargetEntity id="88949446571333" type="siTarget">Tumor necrosis factor receptor superfamily member 1B</TargetEntity><TargetEntity id="764" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Ankylosing spondylitis - China - Aug-2015</FirstLaunched><FirstLaunched>Psoriasis - China - Aug-2015</FirstLaunched><FirstLaunched>Rheumatoid arthritis - China - Aug-2015</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="18">National Science and Technology Major Project</RegulatoryDesignation><RegulatoryDesignation id="19">Special Review Project</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="281">Psoriasis</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="398">Ankylosing spondylitis</Indication></IndicationsPrimary><ActionsPrimary><Action id="721">TNF binding agent</Action><Action id="511">TNF antagonist</Action><Action id="8222">Type II TNF receptor modulator</Action></ActionsPrimary><ActionsSecondary><Action id="396">Immunosuppressant</Action></ActionsSecondary><Technologies><Technology id="84">Protein fusion</Technology><Technology id="962">Biosimilar product</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>L4</Code><Name>IMMUNOSUPPRESSIVE AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-01-04T14:37:52.000Z</LastModificationDate><ChangeDateLast>2019-01-08T00:00:00.000Z</ChangeDateLast><AddedDate>2013-04-04T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1019688" linkType="Company"&gt;Zhejiang Hisun Pharmaceutical&lt;/ulink&gt; has developed and launched Anbainuo,  a biosimilar version of the TNF receptor-IgG1 fusion protein &lt;ulink linkID="4567" linkType="Drug"&gt;etanercept&lt;/ulink&gt;, for the   treatment of mild-to-severe rheumatoid arthritis, ankylosing spondylitis and  plaque psoriasis [&lt;ulink linkID="1342685" linkType="Reference"&gt;1342685&lt;/ulink&gt;], [&lt;ulink linkID="1615899" linkType="Reference"&gt;1615899&lt;/ulink&gt;],  [&lt;ulink linkID="1675986" linkType="Reference"&gt;1675986&lt;/ulink&gt;].   In August 2015, the drug was launched in China [&lt;ulink linkID="1750486" linkType="Reference"&gt;1750486&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In July 2013, an application was filed to launch the product as a class 7 therapeutic biologic in China [&lt;ulink linkID="1615901" linkType="Reference"&gt;1615901&lt;/ulink&gt;]; at that time, the application was granted "Special Review Project" and  "National Science and Technology Major Project" [&lt;ulink linkID="1971654" linkType="Reference"&gt;1971654&lt;/ulink&gt;]. In September 2014, CFDA conducted an in-situ inspection and the drug was expected to be approved soon [&lt;ulink linkID="1615900" linkType="Reference"&gt;1615900&lt;/ulink&gt;]. By March 2015, the project passed the in-situ inspection [&lt;ulink linkID="1658304" linkType="Reference"&gt;1658304&lt;/ulink&gt;].  In April 2015, the launch application was approved [&lt;ulink linkID="1658305" linkType="Reference"&gt;1658305&lt;/ulink&gt;]. In July 2015, the company received GMP certificate for producing Anbainuo, and the CFDA approved the drug for the treatment of moderate to severe active rheumatoid arthritis, active ankylosing spondylitis, and adults patients  with moderate and severe plaque psoriasis [&lt;ulink linkID="1675986" linkType="Reference"&gt;1675986&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By 2011, phase III trials had been completed [&lt;ulink linkID="1615900" linkType="Reference"&gt;1615900&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2005, application to conduct a clinical trial was filed in China; in December 2006, the application was approved  [&lt;ulink linkID="1397917" linkType="Reference"&gt;1397917&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In December 2018, the project received funding from the Chinese government [&lt;ulink linkID="2106997" linkType="Reference"&gt;2106997&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-08-29T00:00:00.000Z</StatusDate><Source id="1750486" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-08-29T00:00:00.000Z</StatusDate><Source id="1750486" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-08-29T00:00:00.000Z</StatusDate><Source id="1750486" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-06-30T00:00:00.000Z</StatusDate><Source id="1397917" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-31T00:00:00.000Z</StatusDate><Source id="1615900" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-11T00:00:00.000Z</StatusDate><Source id="1615901" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-22T00:00:00.000Z</StatusDate><Source id="1658305" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-07-07T00:00:00.000Z</StatusDate><Source id="1675986" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-07-07T00:00:00.000Z</StatusDate><Source id="1675986" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="18">National Science and Technology Major Project</RegulatoryDesignation><OwnerCompany id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="291">Rheumatoid arthritis</Indication><AwardedIndication>Rheumatoid arthritis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-12T00:00:00.000Z</MileStoneDate><Source id="1971654" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="18">National Science and Technology Major Project</RegulatoryDesignation><OwnerCompany id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="281">Psoriasis</Indication><AwardedIndication>Psoriasis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-12T00:00:00.000Z</MileStoneDate><Source id="1971654" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="18">National Science and Technology Major Project</RegulatoryDesignation><OwnerCompany id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="398">Ankylosing spondylitis</Indication><AwardedIndication>Ankylosing spondylitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-12T00:00:00.000Z</MileStoneDate><Source id="1971654" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="19">Special Review Project</RegulatoryDesignation><OwnerCompany id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="398">Ankylosing spondylitis</Indication><AwardedIndication>Ankylosing spondylitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-12T00:00:00.000Z</MileStoneDate><Source id="1971654" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="19">Special Review Project</RegulatoryDesignation><OwnerCompany id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="291">Rheumatoid arthritis</Indication><AwardedIndication>Rheumatoid arthritis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-12T00:00:00.000Z</MileStoneDate><Source id="1971654" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="19">Special Review Project</RegulatoryDesignation><OwnerCompany id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="281">Psoriasis</Indication><AwardedIndication>Psoriasis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-12T00:00:00.000Z</MileStoneDate><Source id="1971654" type="OTHER"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01874"><Name>TNF receptor</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-02033"><Name>Type II TNF receptor</Name><SwissprotNumbers><Swissprot>P20333</Swissprot><Swissprot>P25119</Swissprot><Swissprot>Q80WY6</Swissprot></SwissprotNumbers></Target><Target id="PTGT-03212"><Name>Tumor necrosis factor ligand</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1057639">Chinese Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="252510" title="Chinese Government to award a grant to Zhejiang Hisun to develop etanercept, infliximab, adalimumab and tocilizumab biosimilars"></Deal></Deals><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>